A

Cumulative Incidence of Symptom Resolution, %

Follow Up Days

68.4%
60.4%

Difference in symptom-free days between breakthrough versus non-breakthrough groups:
8.08 d (95% CI, 0.16-81; P=0.0699)

Line Color
Breakthrough
Non-breakthrough

Number at risk

Legend

164 104 88 77 72 65 65
116 62 46 35 25 18 12

Follow Up Days

B

C